Abstract
The prognosis of patients with metastatic melanoma remains poor. In patients with distant metastases only low response rates between 10% and 15% have been achieved by the most effective cytostatics in single-agent therapy leading to a mean 5-year survival rate of less than 5%. More aggressive treatment regimens using multidrug chemotherapy yielded response rates of up to 40% but failed to show a significant benefit in overall survival compared to singleagent therapy. However, complete remissions of metastatic lesions after multidrug cytostatic regimens have been reported in some cases of melanoma patients. To evaluate an in vitro test system providing information on the drug sensitivity profile of melanoma cells, we examined tumor tissue specimens from 31 metastatic melanoma patients with an ATP-based chemosensitivity assay (ATP-TCA) testing eight anticancer drugs alone or in different combinations. Chemosensitivity was assessed using a luciferin-luciferase- based luminescence assay providing individual chemosensitivity indices for each test drug. We found a heterogeneous chemosensitivity in the melanoma tissue samples tested. The highest sensitivity was detected for the combination of treosulfan and gemcitabine, with 76% of the tissue samples revealing high sensitivity and 10% resistance, followed by the combination of paclitaxel and doxorubicine (66%/0%), gemcitabine and cisplatin (55%/21%),and paclitaxel and cisplatin (46%/8%). Our data indicate that the ATP-TCA can be used to select patients who might benefit from an individually adapted cytostatic therapy. On the basis of these results a multicenter trial has recently been initiated to evaluate the feasibility and predictive value of an ATP-TCA directed chemotherapy in metastatic melanoma patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Serrone L, Hersey P (1999) The chemoresistance of human malignant melanoma: an update. Melanoma Res 9:51–58
Helmbach H, Rossmann E, Kern MA, Schadendorf D (2001) Drug-resistance in human melanoma. Int J Cancer 93:617–622
Middleton MR, Lorigan P, Owen J, Ashcroft L, Lee SM, Harper P, Thatcher N (2000) A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer 82:1158–1162
Serrone L, Zeuli M, Sega FM, Cognetti F (2000) Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 19:21–34
Joukhadar C, Klein N, Mader RM, Schrolnberger C, Rizovski B, Heere-Ress E, Pehamberger H, Strauchmann N, Jansen B, Muller M (2001) Penetration of dacarbazine and its active metabolite 5-aminoimidazole-4-carboxamide into cutaneous metastases of human malignant melanoma. Cancer 92:2190–2196
Iqbal M, Marshall E, Green JA (2000) Ten-year survival in advanced malignant melanoma following treatment with interferon and vindesine. Ann Oncol 11:483–485
Metzger U, Rothlin M, Burger HR, Largiader F (1997) Long-term complete remission of melanoma liver metastases after intermittent intra-arterial cisplatin chemotherapy and surgery. Eur J Surg Oncol 23:270–274
Petit T, Borel C, Rixe O, Avril MF, Monnier A, Giroux B, Weil M, Khayat D (1996) Complete remission seven years after treatment for metastatic malignant melanoma. Cancer 77:900–902
Oliver V, Aliaga A, Lopez Lopez JJ, Perez E, Ponchon A, Bizzari JP, Cour V (1993) Long-term complete remissions in patients with disseminated melanoma treated by fotemustine and dacarbazine. Eur J Cancer 29:287
Marshall ES, Finlay GJ, Matthews JH, Shaw JH, Nixon J, Baguley BC (1992) Microculture-based chemosensitivity testing: a feasibility study comparing freshly explanted human melanoma cells with human melanoma cell lines. J Natl Cancer Inst 84:340–345
Schadendorf D, Worm M, Algermissen B, Kohlmus CM, Czarnetzki BM (1994) Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity. Cancer 73:103–108
Schadendorf D, Jurgovsky K, Worm M, Czarnetzki BM (1994) In vitro sensitivity of human melanoma cells to chemotherapeutic agents and interferons. Melanoma Res 4:243–249
Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN (1997) The ex vivo chemosensitivity profile of choroidal melanoma. Anticancer Drugs 8:756–762
Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, Sartori C, Bruckner HW (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276–5282
Kurbacher CM, Cree IA, Bruckner HW, Brenne U, Kurbacher JA, Muller K, Ackermann T, Gilster TJ, Wilhelm LM, Engel H, Mallmann PK, Andreotti PE (1998) Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer. Anticancer Drugs 9:51–57
Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE (1999) Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs 10:437–444
American Joint Committee on Cancer (1977) Staging manual. Lippincott, Philadelphia
Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE, Bruckner HW (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anticancer Drugs 7:630–635
Neale MH, Myatt N, Cree IA, Kurbacher CM, Foss AJ, Hungerford JL, Plowman PN (1999) Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer 79:1487–1493
Kern MA, Helmbach H, Artuc M, Karmann D, Jurgovsky K, Schadendorf D (1997) Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression. Anticancer Res 17:4359–4370
Ichihashi N, Kitajima Y (2001) Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. Br J Dermatol 144:745–750
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Ugurel, S., Tilgen, W., Reinhold, U. (2003). Chemosensitivity Testing in Malignant Melanoma. In: Reinhold, U., Tilgen, W. (eds) Chemosensitivity Testing in Oncology. Recent Results in Cancer Research, vol 161. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19022-3_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-19022-3_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62412-4
Online ISBN: 978-3-642-19022-3
eBook Packages: Springer Book Archive